Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 19 Source: CRO
- €1.3 billion turnover
-
€95.4 million
profit - 714 employees
-
31st Dec 18 Source: CRO
- €839.5 million turnover
-
€95.8 million
profit - 684 employees
- 12 more years available »
Ranking
By Turnover
(€1.3 billion)- 79th in Top Companies
- 12th in Pharma
By Employees
(714)- 282nd in Top Companies
- 23rd in Pharma
-
- 714
- €1.3 billion
Employees
- Johannes Schweppenhäuser Country Manager
Latest News
- May 08 Bank of Ireland paves way for negative rates on accounts with over €1m
- May 08 Air Corps bid for search and rescue services would result in job losses, union warns
- May 08 FBD, ICG and Uniphar under fire over executive pay
- May 07 US jobs growth slows despite reopenings and vaccinations
- May 07 Regulator expects FBD to pay ‘all reasonable costs’ of publicans, court told